TOBRAMYCIN SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C18H37N5O9.5H2O4S
Molecular Weight	1425.421
Optical Activity	UNSPECIFIED
Defined Stereocenters	28 / 28
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O.NC[C@H]4O[C@H](O[C@@H]5[C@@H](N)C[C@@H](N)[C@H](O[C@H]6O[C@H](CO)[C@@H](O)[C@H](N)[C@H]6O)[C@H]5O)[C@H](N)C[C@@H]4O

InChI

InChIKey=NZKFUBQRAWPZJP-BXKLGIMVSA-N

InChI=1S/2C18H37N5O9.5H2O4S/c2*19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;5*1-5(2,3)4/h2*5-18,24-28H,1-4,19-23H2;5*(H2,1,2,3,4)/t2*5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;;;;;/m00...../s1

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H37N5O9
Molecular Weight	467.5145
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	14 / 14
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205433s000lbl.pdf
Curator's Comment: Description was created based on several resourses, including http://www.drugbank.ca/drugs/DB00684

Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, it is effective against gram-negative bacteria, especially the pseudomonas species. Tobramycin is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin. KITABIS PAK (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
30S ribosomal protein S12 20 Target ID: CHEMBL1641336 Sources: http://www.drugbank.ca/drugs/DB00684#targets	Inhibitor 8504		9.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
External infections of the eye 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50541slr017_tobrex_lbl.pdf	Curative		Approved 8583	TOBREX Approved Use external infections of the eye Launch Date 1980
Cystic fibrosis 120 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205433s000lbl.pdf	Primary		Approved 8583	KITABIS PAK Approved Use cystic fibrosis Launch Date 2014

C_max

Value	Dose	Co-administered	Analyte	Population
3.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
814 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN sputum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
11.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4208289/	80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered:		TOBRAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN sputum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	300 mg single, respiratory dose: 300 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TOBRAMYCIN sputum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
12 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 12 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 12 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6440126	unhealthy, 2 months - 27 years Health Status: unhealthy Age Group: 2 months - 27 years Sources: https://pubmed.ncbi.nlm.nih.gov/6440126	Sources: https://pubmed.ncbi.nlm.nih.gov/6440126
300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	Other AEs: Forced expiratory volume decreased, Rales... Other AEs: Forced expiratory volume decreased (31%) Rales (19%) Red blood cell sedimentation rate increased (8%) Dysphonia (6%) Wheezing (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	Other AEs: Hypersensitivity, Eyelids itchy sensation of... Other AEs: Hypersensitivity Eyelids itchy sensation of Swelling Redness of eyelid conjunctiva Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
1.5 mg/kg 3 times / day multiple, intramuscular Dose: 1.5 mg/kg, 3 times / day Route: intramuscular Route: multiple Dose: 1.5 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/820195	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/820195	Sources: https://pubmed.ncbi.nlm.nih.gov/820195
2 mg/kg single, intraperitoneal Dose: 2 mg/kg Route: intraperitoneal Route: single Dose: 2 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/3950451	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/3950451	Sources: https://pubmed.ncbi.nlm.nih.gov/3950451

AEs

AE	Significance	Dose	Population
Rales	19%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Forced expiratory volume decreased	31%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Wheezing	5%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Dysphonia	6%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Red blood cell sedimentation rate increased	8%	300 mg 2 times / day multiple, respiratory Recommended Dose: 300 mg, 2 times / day Route: respiratory Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	unhealthy, >6 years Health Status: unhealthy Age Group: >6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf
Eyelids itchy sensation of		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Hypersensitivity		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Redness of eyelid conjunctiva		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf
Swelling		3 mg 3 times / day multiple, ophthalmic Recommended Dose: 3 mg, 3 times / day Route: ophthalmic Route: multiple Dose: 3 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 OAT1 725 OAT3 747 OAT2 153 OATP1B1 1079 OATP2B1 157 OCT1 620 OCT2 779	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
OATP1B1 1095	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OCT1 656	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OCT2 782	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	minor
OAT2 155	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	no
OATP2B1 162	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 8.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0022354921000708 Page: 1612.0	no
OAT1 730	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	yes
OAT3 749	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0928098718300022 Page: 7.0	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0024320501013753 Page: 2908.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:28864	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28864
ChemicalBook	CB7154445	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7154445
eMolecules	36516853	https://www.emolecules.com/cgi-bin/more?vid=36516853
eMolecules	3716283	https://www.emolecules.com/cgi-bin/more?vid=3716283
MolPort	MolPort-003-665-548	https://www.molport.com/shop/molecule-link/MolPort-003-665-548
Selleck Chemicals	Tobramycin(free-base)	http://www.selleckchem.com/products/Tobramycin(free-base).html
ZINC	ZINC000008214692	http://zinc15.docking.org/substances/ZINC000008214692

PubMed

Title	Date	PubMed
A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea.	2001-11-01	11589975
Gene expression in Pseudomonas aeruginosa biofilms.	2001-10-25	11677611
High-rising terminals and fall-rise tunes in Australian English.	2001-10-20	11641630
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis.	2001-10	11598606
The treatment of cystic fibrosis--step by step.	2001-10	11598588
Effects of antibiotics on morphologic characteristics and migration of canine corneal epithelial cells in tissue culture.	2001-10	11592337
Bacillus cereus keratitis associated with contact lens wear.	2001-10	11581057
Efficacy and safety of aerosolized tobramycin in cystic fibrosis.	2001-10	11568993
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.	2001-10	11568989
Aminoglycoside binding to human and bacterial A-Site rRNA decoding region constructs.	2001-10	11557348
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.	2001-09-22	11583754
The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey.	2001-09	11678929
Isolation and culture of airway epithelial cells from chronically infected human lungs.	2001-09	11669281
[Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of beta-lactam resistance mechanisms: the GERPB 1999 study].	2001-09	11642015
Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin.	2001-09	11587466
Recovery from vestibular ototoxicity.	2001-09	11568676
Defining a pulmonary exacerbation in cystic fibrosis.	2001-09	11562614
A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment.	2001-09	11562127
Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: results of a controlled trial.	2001-09	11555764
Microbiological and immunologic considerations with aerosolized drug delivery.	2001-09	11555566
Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.	2001-09	11555565
Administration of aerosolized antibiotics in cystic fibrosis patients.	2001-09	11555564
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.	2001-09	11549103
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.	2001-09	11533004
Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.	2001-08-02	11478352
The role of nebulized antibiotics in treating serious respiratory infections.	2001-08	11589477
Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site.	2001-08	11587639
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.	2001-08	11558860
Mycobacterium keratitis following hyperopic laser in situ keratomileusis.	2001-08	11548144
Prevalence and analysis of risk factors for infections caused by resistant Escherichia coli strains in Anhui, China.	2001-08	11545486
In vitro elution of tobramycin from bioabsorbable polycaprolactone beads.	2001-08	11514769
Serratia Marcescens corneal ulcer as a complication of orthokeratology.	2001-08	11476690
Selective decontamination of the digestive tract in severely burned pediatric patients.	2001-08	11451595
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.	2001-07-30	11485888
Some 3-thioxo/alkylthio-1,2,4-triazoles with a substituted thiourea moiety as possible antimycobacterials.	2001-07-09	11425542
[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1999)].	2001-07	11560054
Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies.	2001-07	11471880
Recent advances in cystic fibrosis.	2001-07	11420207
In vitro selection of RNA against kanamycin B.	2001-06-30	11459219
Tobramycin (Cystic Fibrosis Foundation/PathoGenesis).	2001-06	11572653
Effective bactericidal activity of tobramycin and vancomycin eluted from acrylic bone cement.	2001-06	11480597
Clinical observation and treatment of leptospirosis.	2001-06	11455495
Changing antibiotic sensitivity patterns at a university hospital, 1992 through 1999.	2001-06	11440331
[Cloning of the sugar related biosynthesis gene cluster from Streptomyces tenebrarius H6].	2001-05	11517612
Natural antibiotic susceptibility of recently established coryneform bacteria.	2001-05	11453591
[Functional characterization of a multiple-antibiotic resistant plasmid from clinical isolates of methicillin-resistant Staphylococcus aureus].	2001-05	11424487
Risk of endotoxemia during the initial phase of gut decontamination with antimicrobial agents.	2001-03	11426668
New and emerging therapies for pulmonary complications of cystic fibrosis.	2001	11558827
Aerosols and anti-infectious agents.	2001	11495486
Outbreak caused by tobramycin-resistant Pseudomonas aeruginosa in a bone marrow transplantation unit.	2001	11450864

Patents

Sample Use Guides

In Vivo Use Guide

KITABIS PAK is a co-packaging of tobramycin inhalation solution ampules with a PARI LC PLUS Reusable Nebulizer. Administer as follows: One single-use ampule (300 mg /5 mL) of tobramycin inhalation solution twice a day by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug. The 300 mg/5mL dose of tobramycin inhalation solution is the same for all patients regardless of age or weight. The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.

Route of Administration: Respiratory

In Vitro Use Guide

High-dose tobramycin (200 ug/ml) killed 72% of Pseudomonas aeruginosa isolates

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:30 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:30 GMT 2025`
Record UNII	HJT0RXD7JK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NEBCIN

Preferred Name

English

TOBRAMYCIN SULFATE

Common Name

English

TOBRAMYCIN SULFATE (2:5)

Common Name

English

GERNEBCIN

Common Name

English

TOBRAMYCIN SULFATE [USP IMPURITY]

Common Name

English

STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1-6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBOHEXOPYRANOSYL-(1-4))-2-DEOXY-, D-, SULPHATE (SALT)

Common Name

English

TOBRADISTIN

Common Name

English

NEBICINA

Common Name

English

TOBRAMYCIN SULFATE [MI]

Common Name

English

TOBRAMYCIN SULPHATE

Common Name

English

D-STREPTAMINE, O-3-AMINO-3-DEOXY-ALPHA-D-GLUCOPYRANOSYL-(1.FWDARW.6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBO-HEXOPYRANOSYL- (1.FWDARW.4))-2-DEOXY-, SULPHATE (2:5) (SALT)

Common Name

English

Tobramycin sulfate [WHO-DD]

Common Name

English

TOBRAMYCIN SULFATE [ORANGE BOOK]

Common Name

English

TOBRA

Common Name

English

OBRACIN

Common Name

English

TOBRAMYCIN SULFATE [USP MONOGRAPH]

Common Name

English

TOBRAMYCIN SULFATE [MART.]

Common Name

English

STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1-6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBOHEXOPYRANOSYL-(1-4))-2-DEOXY-, D-, SULFATE (SALT)

Common Name

English

TOBRAMYCIN SULFATE [VANDF]

Common Name

English

D-STREPTAMINE, O-3-AMINO-3-DEOXY-ALPHA-D-GLUCOPYRANOSYL-(1.FWDARW.6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-ALPHA-D-RIBO-HEXOPYRANOSYL- (1.FWDARW.4))-2-DEOXY-, SULFATE (2:5) (SALT)

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

536416